US6228871B1
(en)
|
1995-07-10 |
2001-05-08 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
HUP9901155A3
(en)
|
1996-02-13 |
2003-04-28 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
CN100503580C
(zh)
|
1996-04-12 |
2009-06-24 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
NZ333382A
(en)
|
1996-06-27 |
2000-05-26 |
Janssen Pharmaceutica Nv |
N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
EP0929526B1
(en)
|
1996-09-25 |
2005-07-27 |
AstraZeneca AB |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
JP2009007364A
(ja)
*
|
1996-10-15 |
2009-01-15 |
Astrazeneca Uk Ltd |
キナゾリン誘導体
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
ZA986729B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
DE69838172T2
(de)
|
1997-08-22 |
2008-04-10 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
US6162804A
(en)
*
|
1997-09-26 |
2000-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6465484B1
(en)
|
1997-09-26 |
2002-10-15 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
FR2772763B1
(fr)
*
|
1997-12-24 |
2004-01-23 |
Sod Conseils Rech Applic |
Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
AP1411A
(en)
|
1998-06-02 |
2005-05-10 |
Osi Pharm Inc |
Pyrrolo[2,3d] pyrimidine compositions and their use.
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
US20040067227A1
(en)
*
|
2001-11-02 |
2004-04-08 |
Goldstein Allan L. |
Inhibition or reversal of skin aging by actin-sequestering peptides
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
PT1154774E
(pt)
*
|
1999-02-10 |
2005-10-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de angiogenese
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
US6399743B1
(en)
|
1999-05-14 |
2002-06-04 |
Dept. Of Veterans Affairs |
Isolation and characterization of a rat epidermal growth factor related protein
|
EA004981B1
(ru)
|
1999-06-21 |
2004-10-28 |
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
KR20020032608A
(ko)
|
1999-09-21 |
2002-05-03 |
다비드 에 질레스 |
퀴나졸린 화합물 및 이를 함유하는 제약 조성물
|
DE60043349D1
(de)
*
|
1999-09-21 |
2009-12-31 |
Astrazeneca Ab |
Chinazolin-derivate und ihre verwendung als arzneimittel
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
DK1676845T3
(da)
|
1999-11-05 |
2008-09-15 |
Astrazeneca Ab |
Nye quinazolinderivater
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
CA2392554A1
(en)
|
1999-11-30 |
2001-06-28 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7160890B2
(en)
*
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
IL151045A0
(en)
|
2000-02-07 |
2003-04-10 |
Abbott Gmbh & Co Kg |
2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AUPQ592100A0
(en)
*
|
2000-02-29 |
2000-03-23 |
Council Of The Queensland Institute Of Medical Research, The |
A method of treatment and prophylaxis
|
AU2001235804A1
(en)
|
2000-03-06 |
2001-09-17 |
Astrazeneca Ab |
Therapy
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
ES2267748T3
(es)
*
|
2000-04-07 |
2007-03-16 |
Astrazeneca Ab |
Compuestos de quinazolina.
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
KR100821446B1
(ko)
|
2000-08-21 |
2008-04-10 |
아스트라제네카 아베 |
퀴나졸린 유도체
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6756383B2
(en)
*
|
2000-09-01 |
2004-06-29 |
Chiron Corporation |
Heterocyclic derivatives of quinolinone benimidazoles
|
ATE386736T1
(de)
|
2000-09-11 |
2008-03-15 |
Novartis Vaccines & Diagnostic |
Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
JP4564713B2
(ja)
|
2000-11-01 |
2010-10-20 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
|
AU2001229722A1
(en)
*
|
2000-11-29 |
2002-06-11 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
US6680324B2
(en)
*
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
CZ304059B6
(cs)
|
2000-12-21 |
2013-09-11 |
Glaxo Group Limited |
Deriváty pyrimidinu a farmaceutický prostredek
|
ME00502B
(me)
|
2001-01-05 |
2011-10-10 |
Amgen Fremont Inc |
Antitjela za insulinu sličan receptor faktora i rasta
|
US20070050857A1
(en)
*
|
2001-02-28 |
2007-03-01 |
Hayward Nick K |
Method of treatment and prophylaxis
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
WO2002092578A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2003000188A2
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
JP4836368B2
(ja)
*
|
2001-08-30 |
2011-12-14 |
広栄化学工業株式会社 |
メチルヒドロキシアルキルピリジン類の製造方法
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
KR20050042055A
(ko)
*
|
2001-11-03 |
2005-05-04 |
아스트라제네카 아베 |
항종양제로서의 퀴나졸린 유도체
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
JP2005529062A
(ja)
*
|
2001-11-30 |
2005-09-29 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
アデノシンa1及びa3受容体に特異的な化合物とその使用
|
ATE519748T1
(de)
*
|
2001-12-19 |
2011-08-15 |
Ube Industries |
Verfahren zur herstellung von chinazolin-4-on und derivaten davon
|
CN101973998A
(zh)
*
|
2001-12-20 |
2011-02-16 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物
|
JP4440642B2
(ja)
|
2001-12-20 |
2010-03-24 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
ピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用
|
US8367824B2
(en)
*
|
2002-01-28 |
2013-02-05 |
Ube Industries Ltd. |
Process for producing quinazolin-4-one derivative
|
US7268230B2
(en)
|
2002-02-01 |
2007-09-11 |
Astrazeneca Ab |
Quinazoline compounds
|
EP1483268A2
(en)
|
2002-03-01 |
2004-12-08 |
Pfizer Inc. |
Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
|
TWI324597B
(en)
*
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
US6936641B2
(en)
*
|
2002-06-25 |
2005-08-30 |
Johnson & Johnson Vision Care, Inc. |
Macromer forming catalysts
|
US7576074B2
(en)
*
|
2002-07-15 |
2009-08-18 |
Rice Kenneth D |
Receptor-type kinase modulators and methods of use
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
BR0313743A
(pt)
*
|
2002-08-23 |
2005-07-05 |
Chiron Corp |
Benzimidazol quinolinonas e usos destas
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
TW200420542A
(en)
|
2002-08-23 |
2004-10-16 |
Kirin Brewery |
A compound having TGF β inhibition activity and a medicinal composition containing the same
|
EP1539713B1
(en)
|
2002-08-24 |
2007-12-19 |
Astrazeneca AB |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
BR0315756A
(pt)
*
|
2002-11-04 |
2005-09-06 |
Astrazeneca Ab |
Derivado de quinazolina ou um seu sal farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de um seu sal farmaceuticamente aceitável, e, método para produzir um efeito anti-invasivo pela detenção e/ou pelo tratamento de doença de tumor sólido em um animal de sangue quente necessitando de tal tratamento
|
EP1565187A4
(en)
*
|
2002-11-13 |
2010-02-17 |
Novartis Vaccines & Diagnostic |
CANCER TREATMENT METHODS AND RELATED METHODS
|
CA2510850A1
(en)
|
2002-12-19 |
2004-07-08 |
Pfizer Inc. |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
|
KR101010299B1
(ko)
|
2002-12-24 |
2011-01-25 |
아스트라제네카 아베 |
포스포노옥시 퀴나졸린 유도체 및 이의 약학적 용도
|
US7223749B2
(en)
*
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
ES2401330T3
(es)
|
2003-02-26 |
2013-04-18 |
Sugen, Inc. |
Compuesto de heteroarilamino inhibidores de proteín quinasas
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
CN102813923B
(zh)
|
2003-08-27 |
2015-04-01 |
奥普索特克公司 |
用于治疗眼新血管疾病的组合治疗
|
MXPA06002296A
(es)
|
2003-08-29 |
2006-05-22 |
Pfizer |
Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
GB0321648D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Astrazeneca Ab |
Quinazoline derivatives
|
MXPA06002964A
(es)
|
2003-09-16 |
2006-06-14 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de cinasa de tirosina.
|
CN1882573A
(zh)
*
|
2003-09-16 |
2006-12-20 |
阿斯利康(瑞典)有限公司 |
作为酪氨酸激酶抑制剂的喹唑啉衍生物
|
ES2281007T3
(es)
*
|
2003-09-19 |
2007-09-16 |
Astrazeneca Ab |
Derivados de quinazolina.
|
AU2004274227B2
(en)
*
|
2003-09-19 |
2008-04-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP2007506716A
(ja)
*
|
2003-09-25 |
2007-03-22 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
WO2005030140A2
(en)
*
|
2003-09-26 |
2005-04-07 |
Exelixis, Inc. |
C-met modulators and methods of use
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
CA2542481A1
(en)
|
2003-10-15 |
2005-04-28 |
Osi Pharmaceuticals, Inc. |
Imidazopyrazine tyrosine kinase inhibitors
|
BRPI0416143A
(pt)
*
|
2003-11-07 |
2007-01-02 |
Chiron Corp |
sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
BRPI0416692A
(pt)
|
2003-11-19 |
2007-01-30 |
Array Biopharma Inc |
inibidores heterocìclicos de mek e métodos de emprego destes
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
JP4503022B2
(ja)
|
2003-12-23 |
2010-07-14 |
ファイザー・インク |
新規キノリン誘導体
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE602004031777D1
(en)
|
2004-01-05 |
2011-04-21 |
Astrazeneca Ab |
Thiophenderivate als chk-1-inhibitoren
|
JP4932495B2
(ja)
|
2004-01-23 |
2012-05-16 |
アムゲン インコーポレイテッド |
化合物及び使用方法
|
JP5019884B2
(ja)
*
|
2004-02-20 |
2012-09-05 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
炎症プロセスおよび転移プロセスの調節
|
JPWO2005080377A1
(ja)
*
|
2004-02-20 |
2007-10-25 |
キリンホールディングス株式会社 |
TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
|
US7534797B2
(en)
|
2004-04-02 |
2009-05-19 |
Osi Pharmaceuticals, Inc. |
6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
ES2374553T3
(es)
|
2004-05-06 |
2012-02-17 |
Warner-Lambert Company Llc |
4-fenilamino-quinazolin-6-il-amidas.
|
EP1756088A1
(en)
*
|
2004-06-04 |
2007-02-28 |
AstraZeneca AB |
Quinazoline derivatives as erbb receptor tyrosine kinases
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
KR20070036130A
(ko)
|
2004-07-16 |
2007-04-02 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
CN101023064B
(zh)
|
2004-08-26 |
2011-02-16 |
辉瑞大药厂 |
作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
|
EP2311827A1
(en)
|
2004-08-28 |
2011-04-20 |
AstraZeneca AB |
Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
|
CA2587642C
(en)
|
2004-11-30 |
2013-04-09 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
EP1838712B8
(en)
|
2004-12-14 |
2011-10-12 |
AstraZeneca AB |
Pyrazolopyrimidine compounds as antitumor agents
|
AU2005319382B2
(en)
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
GB0428526D0
(en)
|
2004-12-30 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
AU2006208012B2
(en)
*
|
2005-01-27 |
2011-08-04 |
Novartis Vaccines And Diagnostics Inc. |
Treatment of metastasized tumors
|
PL1846394T3
(pl)
|
2005-02-04 |
2012-04-30 |
Astrazeneca Ab |
Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
|
KR100910333B1
(ko)
*
|
2005-02-23 |
2009-07-31 |
시오노기세이야쿠가부시키가이샤 |
타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체
|
AR055564A1
(es)
*
|
2005-02-26 |
2007-08-22 |
Astrazeneca Ab |
Derivados de quinazolina
|
GB0504474D0
(en)
*
|
2005-03-04 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
AU2006230563B8
(en)
|
2005-03-31 |
2010-06-17 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
NZ562234A
(en)
|
2005-04-26 |
2009-09-25 |
Pfizer |
P-cadherin antibodies
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
GB0508717D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
CN1858040B
(zh)
*
|
2005-05-08 |
2011-04-06 |
中国科学院上海药物研究所 |
5,8-二取代喹唑啉及其制备方法和用途
|
MX2007014206A
(es)
|
2005-05-13 |
2008-02-07 |
Novartis Ag |
Metodos para tratar cancer resistente a los farmacos.
|
CN101223157B
(zh)
|
2005-05-17 |
2013-03-06 |
诺瓦提斯公司 |
合成杂环化合物的方法
|
BRPI0610139A2
(pt)
|
2005-05-18 |
2010-06-01 |
Array Biopharma Inc |
inibidores heterocìclicos de mek e métodos de uso dos mesmos
|
KR101368519B1
(ko)
*
|
2005-05-23 |
2014-02-27 |
노파르티스 아게 |
결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염
|
KR20080037655A
(ko)
|
2005-07-21 |
2008-04-30 |
아스트라제네카 아베 |
신규 피페리딘 유도체
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
US7566721B2
(en)
*
|
2005-08-08 |
2009-07-28 |
Osi Pharmaceuticals, Inc. |
Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
HUE025608T2
(en)
|
2005-09-07 |
2016-03-29 |
Amgen Fremont Inc |
Human monoclonal antibody against activin receptor-like kinase-1 (ALK-1)
|
US20090239861A1
(en)
*
|
2005-09-20 |
2009-09-24 |
Robert Hugh Bradbury |
Quinazoline derivatives as anticancer agents
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
JPWO2007034882A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
WO2007034881A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
WO2007039736A1
(en)
|
2005-10-06 |
2007-04-12 |
Astrazeneca Ab |
Novel compounds
|
BRPI0618011A2
(pt)
|
2005-10-28 |
2011-08-16 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
|
EP1948179A1
(en)
|
2005-11-11 |
2008-07-30 |
Boehringer Ingelheim International GmbH |
Quinazoline derivatives for the treatment of cancer diseases
|
CA2755268C
(en)
|
2005-11-15 |
2013-12-31 |
Array Biopharma, Inc. |
Erbb inhibitors
|
RU2433826C2
(ru)
|
2005-11-29 |
2011-11-20 |
Новартис Аг |
Композиции хинолинонов
|
JP2009517450A
(ja)
*
|
2005-12-02 |
2009-04-30 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体
|
JP2009517451A
(ja)
*
|
2005-12-02 |
2009-04-30 |
アストラゼネカ アクチボラグ |
Erbbチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体
|
AR057960A1
(es)
*
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
|
TW200732296A
(en)
|
2005-12-15 |
2007-09-01 |
Astrazeneca Ab |
Novel compounds
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
RS20080525A
(en)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CN101454284A
(zh)
|
2006-05-26 |
2009-06-10 |
阿斯利康(瑞典)有限公司 |
联芳基或芳基-杂芳基取代的吲哚类化合物
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
SI2057156T1
(sl)
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
|
RU2492864C2
(ru)
*
|
2006-09-18 |
2013-09-20 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способ лечения рака, несущего мутации egfr
|
US7851623B2
(en)
*
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
US7799954B2
(en)
|
2006-11-17 |
2010-09-21 |
Abraxis Bioscience, Llc |
Dicarbonyl derivatives and methods of use
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
KR20090094460A
(ko)
|
2006-12-19 |
2009-09-07 |
아스트라제네카 아베 |
무스카린 수용체 길항제로서 퀴누클리디놀 유도체
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
US8148532B2
(en)
|
2007-03-14 |
2012-04-03 |
Guoqing Paul Chen |
Spiro substituted compounds as angiogenesis inhibitors
|
PE20081887A1
(es)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
JP5518711B2
(ja)
|
2007-09-07 |
2014-06-11 |
アジェンシス,インコーポレイテッド |
24p4c12タンパク質に結合する抗体および関連分子
|
CN101883778A
(zh)
|
2007-10-04 |
2010-11-10 |
阿斯利康(瑞典)有限公司 |
具有糖皮质激素活性的甾类[3,2-c]吡唑化合物
|
TWI453021B
(zh)
|
2007-10-11 |
2014-09-21 |
Astrazeneca Ab |
新穎蛋白質激酶b抑制劑
|
EP2222675B1
(en)
|
2007-12-19 |
2013-09-11 |
Genentech, Inc. |
5-anilinoimidazopyridines and methods of use
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
NZ586575A
(en)
|
2007-12-21 |
2012-03-30 |
Genentech Inc |
Azaindolizines and methods of use
|
MX343594B
(es)
|
2007-12-21 |
2016-11-11 |
Medimmune Ltd |
Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US20110046144A1
(en)
*
|
2008-01-18 |
2011-02-24 |
Mulvihill Mark J |
Imidazopyrazinol derivatives for the treatment of cancers
|
US8609673B2
(en)
*
|
2008-01-22 |
2013-12-17 |
Concert Pharmaceuticals, Inc. |
Vandetanib derivatives
|
WO2009094216A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Derivatives of gefitinib
|
EA019709B1
(ru)
|
2008-02-07 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Спирогетероциклы и их применение в качестве лекарственных средств
|
EP2254889B1
(en)
|
2008-02-28 |
2012-12-19 |
Merck Patent GmbH |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2303276B1
(en)
|
2008-05-13 |
2013-11-13 |
AstraZeneca AB |
Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
|
WO2009143051A1
(en)
*
|
2008-05-19 |
2009-11-26 |
Osi Pharmaceuticals, Inc. |
Substituted imidazopyr-and imidazotri-azines
|
ES2502527T3
(es)
|
2008-05-27 |
2014-10-03 |
Astrazeneca Ab |
Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados patológicos mediados por PDE4
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
US8211911B2
(en)
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
WO2010045495A2
(en)
|
2008-10-16 |
2010-04-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
CA2746652C
(en)
|
2008-12-11 |
2018-03-06 |
Axcentua Pharmaceuticals Ab |
Crystalline forms of genistein
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
EP2367821B1
(en)
|
2008-12-17 |
2015-09-16 |
Merck Patent GmbH |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
US8853391B2
(en)
|
2008-12-18 |
2014-10-07 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
EP2387563B2
(en)
|
2009-01-16 |
2022-04-27 |
Exelixis, Inc. |
Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
EP3100745B1
(en)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
EP2393814A1
(en)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
AU2010212590B2
(en)
|
2009-02-10 |
2013-01-10 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
MX2011011025A
(es)
|
2009-04-20 |
2011-11-02 |
Osi Pharmaceuticals Llc |
Preparacion de c-piracin-metilaminas.
|
JP2012526138A
(ja)
*
|
2009-05-07 |
2012-10-25 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
副腎皮質癌を治療するためのosi−906の使用
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
HUE044629T2
(hu)
|
2009-07-06 |
2019-11-28 |
Boehringer Ingelheim Int |
Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
|
AU2010273585B2
(en)
|
2009-07-13 |
2015-04-23 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
US20120128670A1
(en)
|
2009-07-31 |
2012-05-24 |
OSI Pharmaceuticals, LLC |
mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
CA2773662A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
BR112012007322A2
(pt)
|
2009-10-02 |
2017-06-06 |
Astrazeneca Ab |
composto de 2-piridona usados como inibidores de neutrófilo elastase
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
CN102812014B
(zh)
|
2009-10-30 |
2016-01-20 |
多美恩医疗公司 |
新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途
|
KR20120113709A
(ko)
|
2009-11-18 |
2012-10-15 |
아스트라제네카 아베 |
벤조이미다졸 화합물 및 그의 용도
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
MX2012006776A
(es)
|
2009-12-14 |
2012-10-05 |
Merck Patent Gmbh |
Inhibidores de la esfingosina quinasa.
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
KR20120096076A
(ko)
|
2009-12-17 |
2012-08-29 |
메르크 파텐트 게엠베하 |
스핑고신 키나아제 저해제
|
WO2011085641A1
(en)
|
2010-01-15 |
2011-07-21 |
Suzhou Neupharma Co., Ltd. |
Certain chemical entities, compositions, and methods
|
JP2013517321A
(ja)
|
2010-01-19 |
2013-05-16 |
アストラゼネカ アクチボラグ |
ピラジン誘導体
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
ES2753748T3
(es)
|
2010-02-12 |
2020-04-14 |
Pfizer |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
EP2582727B8
(en)
|
2010-06-16 |
2017-04-19 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
SG187119A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
RU2013133846A
(ru)
|
2010-12-20 |
2015-01-27 |
Медиммьюн Лимитед |
Антитела против il-18 и их применение
|
EP3453714B1
(en)
|
2011-02-02 |
2020-11-04 |
Suzhou Neupharma Co., Ltd |
Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
|
KR20140010067A
(ko)
|
2011-02-15 |
2014-01-23 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
AU2012216894B2
(en)
|
2011-02-17 |
2016-07-14 |
Cancer Therapeutics Crc Pty Limited |
Selective FAK inhibitors
|
AU2012216893B2
(en)
|
2011-02-17 |
2016-08-11 |
Cancer Therapeutics Crc Pty Limited |
FAK inhibitors
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
ES2724801T3
(es)
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
MX342874B
(es)
|
2011-07-12 |
2016-10-17 |
Astrazeneca Ab |
N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
CN103702990B
(zh)
|
2011-07-27 |
2015-09-09 |
阿斯利康(瑞典)有限公司 |
2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
CN107245056A
(zh)
|
2011-08-26 |
2017-10-13 |
润新生物公司 |
化学实体、组合物及方法
|
CN104080335B
(zh)
|
2011-09-01 |
2017-06-09 |
钱向平 |
某些化学实体、组合物及方法
|
EP3332785B1
(en)
|
2011-09-14 |
2020-05-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
SG2014014450A
(en)
|
2011-09-22 |
2014-09-26 |
Pfizer |
Pyrrolopyrimidine and purine derivatives
|
EP2760458B1
(en)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
CN104271599A
(zh)
|
2011-11-08 |
2015-01-07 |
辉瑞公司 |
使用抗m-csf抗体治疗炎性疾病的方法
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
EP2806874B1
(en)
|
2012-01-25 |
2017-11-15 |
Neupharma, Inc. |
Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
|
MX2014008864A
(es)
|
2012-01-28 |
2014-12-15 |
Merck Patent Gmbh |
Derivados de triazolo[4,5-d]pirimidina.
|
HUE032203T2
(en)
|
2012-02-09 |
2017-08-28 |
Merck Patent Gmbh |
Furo- [3,2-b] pyridine derivatives as TBK1 and IKK inhibitors
|
SI2812323T1
(sl)
|
2012-02-09 |
2016-08-31 |
Merck Patent Gmbh |
Tetrahidro-kinazolinonski derivati kot zaviralci tank in parp
|
US9120804B2
(en)
|
2012-02-21 |
2015-09-01 |
Merck Patent Gmbh |
8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
|
US9073944B2
(en)
|
2012-02-21 |
2015-07-07 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
US20150038527A1
(en)
|
2012-02-21 |
2015-02-05 |
Merck Patent Gmbh |
Furopyridine derivatives
|
CN104159901B
(zh)
|
2012-03-07 |
2016-10-26 |
默克专利股份公司 |
三唑并吡嗪衍生物
|
PL2831077T3
(pl)
|
2012-03-28 |
2016-10-31 |
|
Bicykliczne pochodne pirazynonowe
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
SG11201406238UA
(en)
|
2012-04-05 |
2014-10-30 |
Hoffmann La Roche |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP3453713B1
(en)
|
2012-04-29 |
2021-09-08 |
Neupharma, Inc. |
Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
|
EA027628B1
(ru)
|
2012-05-04 |
2017-08-31 |
Мерк Патент Гмбх |
Производные пирролотриазинона
|
PL2859017T3
(pl)
|
2012-06-08 |
2019-07-31 |
Sutro Biopharma, Inc. |
Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
JP6430936B2
(ja)
|
2012-07-24 |
2018-11-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
関節症の処置のためのヒドロキシスタチン誘導体
|
AU2013301865B2
(en)
|
2012-08-07 |
2017-08-17 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
AU2013301870B2
(en)
|
2012-08-08 |
2017-04-27 |
Merck Patent Gmbh |
(Aza-)isoquinolinone derivatives
|
WO2014026243A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
CN104812389B
(zh)
|
2012-09-24 |
2020-07-17 |
润新生物公司 |
某些化学实体、组合物及方法
|
CN104662006B
(zh)
|
2012-09-26 |
2017-10-24 |
默克专利股份公司 |
作为parp抑制剂的喹唑酮衍生物
|
WO2014063205A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
JP6304776B2
(ja)
|
2012-11-05 |
2018-04-04 |
ジーエムディーエックス カンパニー プロプライエタリー リミテッド |
体細胞突然変異生成の原因を判定するための方法
|
WO2014075077A1
(en)
|
2012-11-12 |
2014-05-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
BR112015010512A2
(pt)
|
2012-11-16 |
2017-07-11 |
Merck Patent Gmbh |
derivados de carboxamida de 3-aminociclopentano
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
RU2656593C2
(ru)
|
2013-01-31 |
2018-06-06 |
Неомед Инститьют |
Соединения имидазопиридина, полезные при лечении состояния, связанного с активностью p2x3 и/или p2x2/3
|
US9663475B2
(en)
|
2013-02-25 |
2017-05-30 |
Merck Patent Gmbh |
2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors
|
WO2014134483A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
AU2014224976B2
(en)
|
2013-03-05 |
2017-09-28 |
Merck Patent Gmbh |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
WO2014151871A2
(en)
|
2013-03-14 |
2014-09-25 |
Tolero Pharmaceuticals, Inc. |
Jak2 and alk2 inhibitors and methods for their use
|
US9937137B2
(en)
|
2013-03-15 |
2018-04-10 |
Neurocentria, Inc. |
Magnesium compositions and uses thereof for cancers
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
WO2014195507A1
(en)
|
2013-06-07 |
2014-12-11 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
US10220053B2
(en)
|
2013-06-25 |
2019-03-05 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
CN111285813A
(zh)
|
2013-08-23 |
2020-06-16 |
润新生物公司 |
化学实体、组合物和方法
|
AU2014324092B2
(en)
|
2013-09-18 |
2020-02-06 |
Epiaxis Therapeutics Pty Ltd |
Stem cell modulation II
|
WO2015048852A1
(en)
|
2013-10-01 |
2015-04-09 |
The University Of Queensland |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US9567643B2
(en)
|
2013-10-04 |
2017-02-14 |
Aptose Biosciences Inc. |
Compositions and methods for treating cancers
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
GB201321146D0
(en)
*
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
CN104829542B
(zh)
*
|
2014-02-10 |
2018-02-02 |
中国科学院上海药物研究所 |
苯胺嘧啶类化合物、其制备方法和医药用途
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
CN106460060B
(zh)
|
2014-04-04 |
2020-02-11 |
中美冠科生物技术(太仓)有限公司 |
Hnf4g-rspo2融合基因及其在癌症治疗中的用途
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
PL3137460T3
(pl)
|
2014-04-30 |
2020-04-30 |
Pfizer Inc. |
Pochodne diheterocyklu połączonego cykloalkilem
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
EP3473271B1
(en)
|
2014-07-31 |
2022-07-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Human monoclonal antibodies against epha4 and their use
|
CN105330653A
(zh)
*
|
2014-08-11 |
2016-02-17 |
石药集团中奇制药技术(石家庄)有限公司 |
喹唑啉衍生物
|
AU2015309686B2
(en)
|
2014-08-25 |
2020-05-14 |
Epiaxis Therapeutics Pty Ltd |
Compositions for modulating cancer stem cells and uses therefor
|
EP3221701B1
(en)
|
2014-11-17 |
2021-03-31 |
The University of Queensland |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
AU2016220219B2
(en)
|
2015-02-17 |
2020-05-14 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9901574B2
(en)
|
2015-04-20 |
2018-02-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
CN107709344B
(zh)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
用于治疗黄病毒科病毒和癌症的核苷类似物
|
CN111349118B
(zh)
|
2015-05-18 |
2023-08-22 |
住友制药肿瘤公司 |
具有增加的生物利用度的阿伏西地前药
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
CA2993659A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
CA2994023A1
(en)
|
2015-08-04 |
2017-02-02 |
University Of South Australia |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
WO2017031551A1
(en)
|
2015-08-26 |
2017-03-02 |
Gmdx Co Pty Ltd |
Methods of detecting cancer recurrence
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
GB201519568D0
(en)
|
2015-11-05 |
2015-12-23 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
CN108601752A
(zh)
|
2015-12-03 |
2018-09-28 |
安吉奥斯医药品有限公司 |
用于治疗mtap缺失型癌症的mat2a抑制剂
|
EP3407917A1
(en)
|
2016-01-27 |
2018-12-05 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
AU2017214761B2
(en)
|
2016-02-01 |
2024-02-01 |
Epiaxis Therapeutics Pty Ltd |
Proteinaceous compounds and uses therefor
|
GB201604182D0
(en)
|
2016-03-11 |
2016-04-27 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
SG11201806982PA
(en)
|
2016-03-21 |
2018-09-27 |
Astrazeneca Ab |
Cinnolin-4-amine compounds and their use in treating cancer
|
MA44603A
(fr)
|
2016-04-07 |
2019-02-13 |
Astrazeneca Ab |
Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer
|
WO2017178845A1
(en)
|
2016-04-15 |
2017-10-19 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
GB201608227D0
(en)
|
2016-05-11 |
2016-06-22 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
TWI817929B
(zh)
|
2016-07-29 |
2023-10-11 |
美商瑞佩特治療公司 |
趨化介素受體調節劑及其用途
|
EP4006035B1
(en)
|
2016-08-15 |
2023-11-22 |
Neupharma, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
CN110036006B
(zh)
|
2016-09-22 |
2022-12-13 |
癌症研究科技有限公司 |
嘧啶酮衍生物的制备和用途
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
MX2019007332A
(es)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Péptidos indicadores y métodos para caracterizar sensibilidad.
|
BR112019012217B1
(pt)
|
2016-12-20 |
2021-08-10 |
Astrazeneca Ab |
Compostos, formas cristalinas, composição farmacêutica e uso de um composto ou seu sal farmaceuticamente aceitável
|
JP7113528B2
(ja)
|
2017-02-01 |
2022-08-05 |
オーセントラ セラピュティクス ピーティーワイ エルティーディー |
治療薬としてのN-シクロアルキル/ヘテロシクロアルキル-4-(イミダゾ[1,2-a]ピリジン)ピリミジン-2-アミン誘導体
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
JOP20190209A1
(ar)
|
2017-03-16 |
2019-09-12 |
Astrazeneca Ab |
مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
WO2018215798A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
EP3630188B1
(en)
|
2017-05-31 |
2021-08-25 |
Amplio Pharma AB |
A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
US11319304B2
(en)
*
|
2017-06-28 |
2022-05-03 |
Vanderbilt University |
Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
WO2019007447A1
(en)
|
2017-07-05 |
2019-01-10 |
E.P.O.S Iasis Research And Development Limited |
MULTIFUNCTIONAL CONJUGATES
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
PT3661941T
(pt)
|
2017-08-01 |
2023-03-16 |
Merck Patent Gmbh |
Derivados tiazolopiridina como antagonistas do recetor de adenosina
|
CA3070903A1
(en)
|
2017-08-18 |
2019-02-21 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
EP3672952B1
(en)
|
2017-08-21 |
2022-12-14 |
Merck Patent GmbH |
Benzimidazole derivatives as adenosine receptor antagonists
|
CA3073343A1
(en)
|
2017-08-21 |
2019-02-28 |
Merck Patent Gmbh |
Quinoxaline derivatives as adenosine receptor antagonists
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
RU2020111503A
(ru)
|
2017-09-18 |
2021-10-20 |
Сутро Биофарма, Инк. |
Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение
|
CN111344293A
(zh)
|
2017-09-20 |
2020-06-26 |
阿斯利康(瑞典)有限公司 |
1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
IL274444B1
(en)
|
2017-11-06 |
2024-02-01 |
Rapt Therapeutics Inc |
Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
ES2965337T3
(es)
|
2017-11-23 |
2024-04-12 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Composición farmacéutica para administración oral que contiene sulfasalazina y/o una sal orgánica de sulfasalazina, proceso de producción y uso
|
US11325900B2
(en)
|
2018-01-15 |
2022-05-10 |
Aucentra Holdings Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
MX2020007812A
(es)
|
2018-01-26 |
2020-11-24 |
Rapt Therapeutics Inc |
Moduladores del receptor de quimiocina y usos de los mismos.
|
KR20200143361A
(ko)
|
2018-02-08 |
2020-12-23 |
뉴파마, 인크. |
특정 화학 물질, 조성물, 및 방법
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
BR112020020832A2
(pt)
|
2018-04-13 |
2021-01-19 |
Cancer Research Technology Limited |
Inibidores de bcl6
|
EP3784233A4
(en)
|
2018-04-27 |
2022-03-02 |
Spruce Biosciences, Inc. |
METHODS OF TREATMENT OF TESTIC AND OVARIAN ADRENAL TUMORS
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
TW202003475A
(zh)
|
2018-06-04 |
2020-01-16 |
美商亞博創新醫藥有限公司 |
含酸性基團之嘧啶化合物
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
JP2022505872A
(ja)
|
2018-10-25 |
2022-01-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
|
SG11202104078PA
(en)
|
2018-10-25 |
2021-05-28 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
WO2020132844A1
(zh)
|
2018-12-25 |
2020-07-02 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
EP3935049A1
(en)
|
2019-03-07 |
2022-01-12 |
Merck Patent GmbH |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
US11712433B2
(en)
|
2019-03-22 |
2023-08-01 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
WO2020201773A1
(en)
|
2019-04-05 |
2020-10-08 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
TW202104194A
(zh)
|
2019-04-08 |
2021-02-01 |
德商馬克專利公司 |
作為shp2拮抗劑的嘧啶酮衍生物
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Fgfr阻害剤とするピラゾール類誘導体及びその調製方法
|
MX2022003276A
(es)
|
2019-09-20 |
2022-04-11 |
Ideaya Biosciences Inc |
Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg.
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
CN115151540A
(zh)
|
2019-12-02 |
2022-10-04 |
风暴治疗有限公司 |
作为mettl3抑制剂的多杂环化合物
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
US20230391770A1
(en)
|
2020-10-06 |
2023-12-07 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
WO2022074391A1
(en)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Compounds inhibitors of mettl3
|
EP3992191A1
(en)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
EP4333900A2
(en)
|
2021-05-03 |
2024-03-13 |
Merck Patent GmbH |
Her2 targeting fc antigen binding fragment-drug conjugates
|
IL308518A
(en)
|
2021-05-17 |
2024-01-01 |
Hk Inno N Corp |
History of benzamide, a method for their preparation and a pharmaceutical preparation for use in the prevention or treatment of cancer containing them as an active ingredient
|
IL308818A
(en)
|
2021-05-25 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting EGFR
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023186881A1
(en)
|
2022-03-29 |
2023-10-05 |
Baden-Württemberg Stiftung Ggmbh |
P38 map kinase inhibitors for use in the treatment of colorectal cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|